Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy.
We report an immunohistochemical investigation of the striatal efferents in the striatum, globus pallidus, and substantia nigra of five patients with multiple system atrophy (MSA): olivopontocerebellar atrophy (2), striatonigral degeneration (2), and Shy-Drager syndrome (1). All patients manifested parkinsonism during the clinical course of their illness. The administration of levodopa improved the symptoms of two patients, but not of the other three. Brain tissues from five age-matched neurologically normal subjects served as controls. Immunohistochemical assays were carried with antibodies against met-enkephalin, substance P, and calbindin-D28k. Irrespective of the clinical form of multiple system atrophy, the immunoreactivity with the antibodies was reduced at the dorsolateral portion of the striatum and the ventrolateral portions of the globus pallidus and of the substantia nigra. The woolly fiber arrangement of reaction product deposits seen in both segments of the globus pallidus of normal individuals was totally absent in the ventrolateral portions of the three patients who did not have a response to levodopa. By contrast, there were positively stained woolly fibers in globus pallidum segments of the two levodopa-responsive patients, even though their number and size were decreased in comparison with controls. These results indicate that the three clinical forms of multiple system atrophy share common topographic alterations of the striatal efferent system and that the severity of the involvement correlates with the clinically observed effect of levodopa on the parkinsonism.
Ito
H
H
Department of Neurology, Kitano Hospital and Neurological Center, Osaka, Japan.
Kusaka
H
H
Matsumoto
S
S
Imai
T
T
D000368:Aged; D003342:Corpus Striatum / Q000473:pathology*; D004525:Efferent Pathways / Q000473:pathology; D005260:Female; D005917:Globus Pallidus / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009849:Olivopontocerebellar Atrophies / Q000188:drug therapy* / Q000473:pathology*
D007980:Levodopa